^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BNT113
i
Other names: BNT113, HPV FixVAC, Hare-40 FixVAC, RBLO 15.1(LIP)/RBLO 16.1(LIP), E6/E7 RNA(LIP), HPV mRNA vaccine, HPV anti-CD40 RNA vaccine
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BioNTech
Drug class:
HPV-16 E6 protein inhibitor, HPV-16 E7 protein inhibitor
Related drugs:
4ms
HARE-40: HPV Anti-CD40 RNA vaccinE (clinicaltrials.gov)
P1/2, N=32, Completed, University of Southampton | Active, not recruiting --> Completed
Trial completion
|
BNT113
5ms
AHEAD-MERIT: A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (clinicaltrials.gov)
P2, N=285, Recruiting, BioNTech SE
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • BNT113
over1year
AHEAD-MERIT: A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (clinicaltrials.gov)
P2; Trial completion date: May 2025 --> May 2028 | Trial primary completion date: May 2025 --> May 2028
Combination therapy • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • BNT113
3years
AHEAD-MERIT: A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (clinicaltrials.gov)
P2, N=285, Recruiting, BioNTech SE | Not yet recruiting --> Recruiting
Clinical • Enrollment open • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • BNT113
over3years
AHEAD-MERIT: A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (clinicaltrials.gov)
P2, N=285, Not yet recruiting, BioNTech SE
Clinical • New P2 trial • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • BNT113
Share via
